ALDEYRA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Debt Securities, Available-for-sale, Unrealized Loss of $103.94 thousand for the 12-month period ending 2022-12-31, per its 10-Q filed 2023-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2023-11-03
- ALDEYRA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-06-30 was $224.09K.
- ALDEYRA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-03-31 was $61.68K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|
| 2022-12-31 | $103.94K 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $224.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $285.76K 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $61.68K 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |